ArticleEuropean journal of nuclear medicine and molecular imaging2015
Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization.
Article in European journal of nuclear medicine and molecular imaging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- PET/MRI in prostate cancer: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2021Pooled it
- Trial
- The Role of [Biomedicines · 2022Article
- Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends.Cancers · 2021Review
- KSNM60 in Clinical Nuclear Oncology.Nuclear medicine and molecular imaging · 2021Review
- MRI/PET Imaging in elevated PSA and localized prostate cancer: a narrative review.Translational andrology and urology · 2021Review
- Diagnostic efficiency of hybrid imaging using PSMA ligands, PET/CT, PET/MRI and MRI in identifying malignant prostate lesions.Annals of nuclear medicine · 2021Article
- The Role of [Cancers · 2021Article
- Value ofFrontiers in oncology · 2020Article
- Imaging modalities in synchronous oligometastatic prostate cancer.World journal of urology · 2019Review
- Summary of the First ISMRM-SNMMI Workshop on PET/MRI: Applications and Limitations.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- Metabolic Volumetric Parameters inContrast media & molecular imaging · 2018Article
- Performance ofCurrent urology reports · 2017Review
- Target Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular Imaging.Frontiers in oncology · 2016Review
- Prognostic Value of Metabolic Tumor Volume on (11)C-Methionine PET in Predicting Progression-Free Survival in High-Grade Glioma.Nuclear medicine and molecular imaging · 2015Article
- PET/MRI in Oncological Imaging: State of the Art.Diagnostics (Basel, Switzerland) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to determine the usefulness of MRI-assisted positron emission tomography (PET) parameters provided by simultaneous (18)F-fluorocholine (FCH) PET/MRI for characterization of primary prostate cancer.
methodsThirty patients with localized prostate cancer (mean age 69.4 ± 6.7 years) confirmed by biopsy were prospectively enrolled for simultaneous PET/MRI imaging. The patients underwent (18)F-FCH PET/MRI 1 week before undergoing total prostatectomy. Multiple parameters of diffusion-weighted MRI [minimum and mean apparent diffusion coefficient (ADCmin and ADCmean)], metabolic PET [maximum and mean standardized uptake value (SUVmax and SUVmean)], and metabolic volumetric PET [metabolic tumor volume (MTV) and uptake volume product (UVP)] were compared with laboratory, pathologic, and immunohistochemical (IHC) features of the prostate cancer specimen. PET parameters were divided into two categories as follows: volume of interest (VOI) of prostate by SUV cutoff 2.5 (SUVmax, SUVmean, MTVSUV, and UVPSUV) and MRI-assisted VOI of prostate cancer (SUVmaxMRI, SUVmeanMRI, MTVMRI, and UVPMRI).
resultsThe rates of prostate cancer-positive cases identified by MRI alone, (18)F-FCH PET alone, and (18)F-FCH PET/MRI were 83.3, 80.0, and 93.3%, respectively. Among the multiple PET/MRI parameters, MTVMRI showed fair correlation with serum prostate-specific antigen (PSA; r = 0.442, p = 0.014) and highest correlation with tumor volume (r = 0.953, p < 0.001). UVPMRI showed highest correlation with serum PSA (r = 0.531, p = 0.003), good correlation with tumor volume (r = 0.908, p < 0.001), and it was significantly associated with Gleason score (p = 0.041). High MTVMRI and UVPMRI values were significant for perineural invasion, lymphatic invasion, extracapsular extension, seminal vesicle invasion, and positive B-cell lymphoma 2 (Bcl-2) expression (all p < 0.05).
conclusionSimultaneous (18)F-FCH PET/MRI demonstrated a better diagnostic value for localized prostate cancer detection than each individual modality. MRI-assisted metabolic volumetric PET parameters (MTVMRI and UVPMRI) provided more accurate characterization of prostate cancer than conventional PET and MRI parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.